Carmell Therapeutics biologic for accelerated bone healing gains expedited review

Alan Condon -   Print  |

The FDA granted Carmell Therapeutics Fast Track designation on April 27 for its debut product, a bone healing accelerant, OA Online reports.

Three things to know:

1. Carmell Therapeutics develops plasma-based bioactive materials to accelerate bone and soft tissue healing.

2. In a Phase II clinical trial for open tibia fractures, the company's bone healing accelerant showed a significant reduction of infections compared to controls, with a clear path toward accelerated wound healing at 30 days.

3. The product can be administered in several forms, including putties, pastes and surgical screws.

More articles on biologics:
AAOS publishes clinical considerations for return to elective surgery
97% of medical practices suffer COVID-19 financial hit: 5 observations for orthopedics
Investor pays $49M for Arizona spine, orthopedic hospital property

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers